NATTOPHARMA – LAST TRADING DAY AT NASDAQ FIRST NORTH

Nasdaq has approved NattoPharma ASA’s application of delisting from the market place Nasdaq First North.

Last trading day for the NattoPharma share (ticker: NATTO, ISIN: NO0010289200) is set to be September 25th, 2018.

The shareholders in NattoPharma whose shares are currently registered on Nasdaq First North will still be able to trade their shares by transferring the shares to “Norwegian” shares. Shareholders who own shares through trustees will be able to continue to buy and sell shares through their trading channels at their nominee banks in line with today's solution. The disadvantages of the delisting from Nasdaq First North are thus very limited for shareholders whose shares per today is listed there.

NattoPharma has engaged Eminova Fondkommission AB to assist in the practical management of transferring the shares currently listed at Nasdaq First North to a trading account at Oslo Axess. For further information about how to proceed to ensure the safe transfer of shares, please contact; Eminova Fondkommission AB by phone on +46 08-68421100 or by email to info@eminova.se

Avanza Bank is acting as NattoPharmas's Certified Adviser on Nasdaq First North.

As previously mentioned, NattoPharma ASA will continue its listing on Oslo Axess and will also fulfill all requirements Oslo Børs / Oslo Axess proposes to issuers of shares in the open marketplace. This will further safeguard the interests of Swedish shareholders in continuous information about significant events in NattoPharma ASA following the delisting from Nasdaq First North. Any shareholder who wishes to receive ongoing information in connection with the company's messages to Oslo Axess may subscribe to automatic messages from the company when such items are sent through the company's news service.

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 15:00 am CET on August 30th, 2018.